drugset / Trial / NCT00966693
Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma
Phase 1/2
Completed
77 enrolled
M.D. Anderson Cancer Center
National Cancer Institute (NCI) · collab
NaSequentialOpen-labelTreatment
Summary
This phase I/II trial studies the best dose and side effects of lenalidomide and thalidomide, and how well they work with dexamethasone in treating participants with multiple myeloma that has come back or does not respond to treatment. Drugs used in chemotherapy, such as lenalidomide, thalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Timeline
- Start
- 2009-08-25
- Primary completion
- 2018-07-20
- Completion
- 2018-07-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | — | Oral |
| Subject | Lenalidomide | Other / unclassified | — | Oral |
| Subject | Thalidomide | Other / unclassified | — | Oral |